Rilzabrutinib

Overview

Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase ( BTK ) , with an IC 50 of 1.3 nM.

Application

Products | Products > Disease Areas > Arthritis | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Autoimmune Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Btk

Product Information

• Catalog No.: HY-112166
• CAS No.: 1575596-29-0
• Molecular Formula: C36H40FN9O3
• Molecular Weight: 665.76
• Purity: 98.97%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (3.12 mM); Clear solution
• Availability: In-stock

Source

Original product source